Shattuck Labs Announces Participation in Investor Conferences
Shattuck Labs, Inc. is gearing up to present at various investor conferences this December, showcasing its innovative work in the field of biotechnology. The company, which operates at the cutting edge of developing therapeutics targeting the tumor necrosis factor (TNF) superfamily receptors, is committed to addressing significant medical challenges associated with inflammatory and immune-mediated diseases.
Upcoming Conference Details
The first pivotal event is the Piper Sandler 37th Annual Healthcare Conference. This event will feature a presentation by Chief Executive Officer, Dr. Taylor Schreiber. Scheduled for December 2, 2025, at 10:10 AM EST, the presentation will take place in New York. Attendees can anticipate engaging discussions and insights reflecting the company's cutting-edge research and development strategies.
Key Presentation Insights
During Dr. Schreiber’s presentation, Shattuck Labs aims to highlight its progress and future direction concerning its novel therapeutics. This event represents a significant opportunity for investors and stakeholders to gain deeper insights into the company's strategic vision and operational advancements.
Additional Investor Engagement
Following the Piper Sandler Conference, Shattuck Labs will participate in the Evercore ISI 8th Annual HealthCONx Conference. Slated for December 3-4, this conference will include a fireside chat featuring Dr. Schreiber and other industry experts. The fireside chat is set for December 4, 2025, at 8:20 AM EST in Coral Gables, FL. This format promises an engaging dialogue, fostering connections with investors and thought leaders within the healthcare sector.
What to Expect from the Fireside Chat
Investors can look forward to an interactive session, where attendees will explore the latest trends and Shattuck Labs’ strategic initiatives in developing therapies for challenging health conditions. The dialogue is expected to touch upon critical areas of growth and innovation that are poised to set the company apart in the biotechnology landscape.
Presentation Replays and Accessibility
For those unable to attend the live presentations, Shattuck Labs will make recordings available. Both sessions from the Piper Sandler and Evercore ISI conferences will be archived and accessible on the company’s official website for up to 30 days post-event. This initiative underscores Shattuck Labs’ commitment to transparency and investor engagement.
About SL-325: A Game-Changer in Treatment
One of Shattuck Labs’ flagship developments is SL-325, a potential first-in-class antibody designed to inhibit Death Receptor 3 (DR3). This innovation aims to provide comprehensive and durable blockage of a vital disease pathway, showing promise in preclinical studies. The data supporting SL-325 illustrates its ability to bind effectively and outperform traditional treatments targeting TL1A.
Clinical Trials and Future Prospects
Currently being evaluated in a Phase 1 clinical trial, SL-325 represents a significant advancement in therapeutic options for patients with inflammatory and immune-mediated diseases. The company is dedicated to ensuring rigorous clinical evaluation, reinforcing its standing as a leader in the biotech industry.
About Shattuck Labs, Inc.
Shattuck Labs, Inc. (NASDAQ: STTK) is a clinical-stage biotechnology firm focusing on groundbreaking research to develop potential treatments for various inflammatory and immune-mediated diseases. Their pioneering work in antibody development is designed to address significant medical challenges, setting the firm on a path for impactful contributions to healthcare. The company operates from facilities in both Austin, Texas, and Durham, North Carolina.
For further inquiries, please reach out via email: InvestorRelations@shattucklabs.com.
Frequently Asked Questions
What is SL-325 and how does it work?
SL-325 is a new antibody designed to block the Death Receptor 3 pathway, which plays a crucial role in inflammatory diseases, aiming for better treatment outcomes.
Where will the upcoming conferences take place?
The Piper Sandler conference will be held in New York, while the Evercore ISI HealthCONx Conference is taking place in Coral Gables, Florida.
Who is presenting at these conferences?
Dr. Taylor Schreiber, CEO of Shattuck Labs, will be the lead presenter, showcasing the company's advancements and research initiatives.
Will the presentations be available after the conferences?
Yes, recordings of the presentations will be available on the company’s website for up to 30 days after each event.
What other developments is Shattuck Labs working on?
In addition to SL-325, Shattuck Labs is focused on various antibody treatments for inflammatory and immune-mediated diseases, leveraging its expertise in protein engineering.
